Brokers Offer Predictions for Bio-Path Holdings, Inc.’s Q2 2024 Earnings (NASDAQ:BPTH)

Bio-Path Holdings, Inc. (NASDAQ:BPTH) – Roth Capital lifted their Q2 2024 EPS estimates for Bio-Path in a research report issued to clients and investors on Monday, June 17th. Roth Capital analyst J. Aschoff now anticipates that the company will earn ($1.54) per share for the quarter, up from their previous estimate of ($2.06). The consensus estimate for Bio-Path’s current full-year earnings is ($9.68) per share. Roth Capital also issued estimates for Bio-Path’s Q3 2024 earnings at ($0.93) EPS, Q4 2024 earnings at ($0.93) EPS, FY2024 earnings at ($5.53) EPS, FY2025 earnings at ($3.65) EPS, FY2026 earnings at ($3.52) EPS, FY2027 earnings at ($3.40) EPS and FY2028 earnings at $5.19 EPS.

Bio-Path (NASDAQ:BPTH) last issued its earnings results on Wednesday, May 15th. The company reported ($4.88) earnings per share for the quarter, missing the consensus estimate of ($4.54) by ($0.34).

Several other research firms have also commented on BPTH. Roth Mkm reiterated a “buy” rating and issued a $40.00 price target on shares of Bio-Path in a research report on Thursday, April 18th. StockNews.com initiated coverage on shares of Bio-Path in a research report on Thursday, May 2nd. They issued a “sell” rating on the stock.

Bio-Path Trading Down 5.0 %

BPTH stock opened at $2.27 on Wednesday. The company’s 50 day simple moving average is $2.65 and its 200-day simple moving average is $6.06. Bio-Path has a 12 month low of $1.85 and a 12 month high of $44.80.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.